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Abstract
Authors summarize in this brief review results of European discussion, held on ETA-CRN Meeting in Lisbon, 2009,
on the American Thyroid Association Medullary Thyroid Cancer (MTC) Guidelines published in the same year and
focus on the timing of prophylactic thyroidectomy. ATA 2009 guidelines classified RET protooncogene mutation
carriers into 4 levels: A, B, C, D. ATA for prophylactic thyroidectomy were generally independent of the serum
calcitonin (Ct) concentration but based on a priori risk levels. This was well accepted as the important novelty was
to delineate risk level specially for RET 634 mutation (level C). In the ATA Guidelines total prophylactic
thyroidectomy below age 5 years was recommended in RET 634 mutation carriers regardless of Ct status. However,
some European experts favored to base the decision not only on the results of DNA testing but also on the going
Ct level. The European discussion reflected divergent opinions and indicated the need of publication of European
experience instead of arbitrary opinions. It was stressed that patients carrying the same RET mutation present
heterogenic progression to the clinically overt medullary thyroid cancer, even in the same family. Thus, in
summary, the ATA MTC guidelines constituted a positive stimulus to publish further evidence for Ct-guided pre-
emptive thyroidectomy for RET gene mutation carriers and the conclusion is drawn on the basis of experience
expressed in Lisbon and published later evidence that the integrated algorithm based on age - Ct - type of RET
mutation should be considered in the decision of pre-emptive thyroidectomy.
In 1993 germline mutations of RET were discovered in her-
editary medullary thyroid cancer [1,2]. Within a few years
DNA testing of protooncogene RET mutations was pro-
posed to patients and their families [3]. To avoid medullary
thyroid cancer development prophylactic (pre-emptive)
thyroidectomy was indicated in identified mutated RET
gene carriers [4]. A few years later, in 2001 for diagnosis
and therapy of MEN [5], known as Gubbio consensus, pro-
posed to relate the timing of prophylactic thyroid operation
to the type of mutation depending on three defined levels
of risk: 1, 2 and 3. In summary, in MEN 2B patients (level
3, RET 918) prophylactic thyroidectomy with central lymph
node dissection (extended lymphadenectomy in the case
of lymph node metastasis identification) was recommended
within first 6 months of life (preferably within the first
month). Young patients with RET 611, 618, 620 and 634
mutations were classified as level 2 of MTC risk in whom
prophylactic thyroid operation should be performed before
the age 5 years. The extension of lymphadenectomy for
each level of risk was not equivocally indicated. Level 1
included 609, 768, 790, 791, 804, and 891 RET mutations
with the lowest risk of MTC. Different strategies for level 1
were presented: 1) prophylactic thyroidectomy before age 5,
2) prophylactic thyroidectomy before the age 10, 3) prophy-
lactic thyroidectomy at the time of abnormal result of
pentagastrin-stimulated Ct test.
In 2009 American Thyroid Association published guide-
lines [6] where the risk of medullary thyroid cancer was
classified into 4 levels: A, B, C, D. ATA for prophylactic
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thyroidectomy were generally independent of serum calci-
tonin (Ct) concentration but based on a priori risk levels.
Level D includes MEN 2B cases where prophylactic thyroi-
dectomy is recommended within the first year of life, as
soon as possible. In children above one year of age pro-
phylactic dissection of the central lymph node compart-
ment is recommended. The ATA guidelines indicated that
there was insufficient data to recommend central lympha-
denectomy in MEN 2B children below 1 year and warned
that the normal range of serum Ct concentration for small
children was unknown.
The important novelty was to delineate risk level spe-
cially for RET 634 mutation (level C). Total thyroidect-
omy below 5 years was recommended in RET 634
mutation carriers regardless of Ct status. In level B (RET
611, 618, 620) thyroid surgery should be done before the
age 5 years. In level B and A (rare RET mutations with
low gene penetrance ex. RET 768, 790, 804, 891) thyroi-
dectomy could be postponed beyond the age 5 years in
families with less aggressive MTC history and in consid-
eration of family preference, if basal ± stimulated serum
Ct and thyroid ultrasound were normal. ATA recom-
mended central and lateral lymphadenectomy in levels
A-C in the case of clinically evident lymph node metas-
tases (image or biopsy positive).
This subdivision to four risk levels was generally very
well accepted, because all felt the need to differ RET 634
mutation from other exon 10/11 mutations [7]. However,
the indications to prophylactic thyroidectomy were eval-
uated as arbitrary. Already after publication of the ATA
Guidelines, in 2012 Elisei and co-workers [8] presented a
study of 84 RET gene mutation carriers with MEN 2A
and FMTC where thyroidectomy was proposed to RET
mutation carriers with elevated serum Ct concentrations
independently of the age and type of RET mutation sta-
tus. Patients with basal and/or stimulated elevated Ct
(both > 10 pg/ml, equal to >10 ng/L) were referred to
thyroid operation. Among the presented group there
were 21 patients with elevated basal Ct at the moment of
their RET mutation status identification. Thirty one RET
gene carriers presented normal basal Ct levels with a
positive pentagastrin test and thirty two patients were
basal Ct negative during follow-up (for 2-16 years). The
authors did not observe any correlation between the age
of gene carriers’ or with type of RET mutation and basal
Ct level. Similarly, no correlation between serum Ct and
the ATA risk level (A, B or C) was observed at the time
of thyroidectomy. The authors decided on the basis of
elevated Ct level and fifty one patients with elevated basal
and/or stimulated Ct level underwent thyroidectomy. All
patients with basal hypercalcitoninaemia were diagnosed
with MTC. In the group with elevated stimulated Ct 25
of 31 patients were diagnosed with MTC but all in sta-
dium pT1N0 (tumor diameter 0.38 cm ± 0,1) and the
rest (6/31) were diagnosed with C cell hyperplasia. The
authors also analyzed the risk of lymph node metastases
in correlation to the basal Ct level. The proposed cut-off
for basal Ct of less than 60 pg/ml (60 ng/L) unequivocally
distinguished patients without lymph node involvement
(sensitivity 100%, specificity 86,5%). It may be concluded,
that authors preferred decisions based on serum Ct than
proposed ATA risk levels.
Machens and Dralle in their editorial published in
Thyroid in 2009 [9] point out that patients carrying the
same mutation even in the same family present hetero-
genic progression to clinically overt medullary thyroid
cancer. Authors propose the integrated DNA and bio-
chemical based concept of prophylactic thyroidectomy.
The moment of C-cell transition to medullary thyroid
cancer usually occurs when stimulated Ct level rises.
When basal Ct starts to increase, the opportunity of
medullary thyroid cancer significantly occurs. Authors
present skeptic evaluation of ATA absolute thresholds
for systemic lymph node dissection. The recommended
cut-offs: primary tumor size of 5 mm and basal Ct of 40
pg/ml need further evaluation and confirmation in the
independent studies.
Also, Rohmer et al. [10] performed with the French
Group of Endocrine Tumors a retrospective multicentre
analysis of 170 young (under 21) patients from hereditary
MTC families. Retrospective analysis included patients
operated from 1977 to 2006. The RET status in many
cases was assessed retrospectively. The age at thyroidect-
omy and its extension were dependent on the type of
mutation (if available) and preoperative Ct serum level.
In this group 92.4% and 38.3% of patients had elevated
stimulated and basal Ct, respectively. All 170 patients
underwent total thyroidectomy, among them 106 with
central and 33 with additionally lateral lymph node dis-
section. Regardless of the ATA risk level all patients
operated with basal Ct below 30 pg/ml (30 ng/L) were
cured. The authors suggested that time of prophylactic
thyroidectomy should always be dependent on preopera-
tive Ct serum concentration rather than risk class with
exception of MEN 2B where operation should be per-
formed as soon as possible. Similarly a Ct serum concen-
tration above 10 pg/ml was proposed cut-off for lymph
node dissection. Rohmer and co-workers did not find any
improvement when analyzing stimulated Ct compared to
its basal concentration.
Similar position is presented in a retrospective study by
Wloch, 2007 [11] where 119 RET carriers underwent thyr-
oidectomy up to 2007. The decision about the age and
extent of prophylactic thyroidectomy in RET gene carriers
was individualized depending on Ct level. The increase of
Ct level was a major factor determining the indication to
earlier surgery. In case of familial history suggesting a mild
phenotype of disease (especially patients with mutation in
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codon 791) author postponed the decision about surgery
up to age of 5-10 years, and in some families even to the
age of 10-18 assumed that stimulated Ct was rigorously
monitored.
In fact, in many studies Ct proved to be a good cancer
marker. Its concentration was strictly correlated with
tumor mass [12]. When basal and stimulated Ct levels
were within normal range histopathological examination
usually revealed at most C-cell hyperplasia. In the
patients showing positive stimulation test C-cell hyper-
plasia or medullary microcarcinoma was diagnosed.
Increasing Ct level (both basal and stimulated) was cor-
related with more advanced medullary cancer. Also, the
risk of central nodes metastases, lateral nodes involve-
ment and distant metastases was correlated with high
Ct level [10]. This problem has been discussed within
the ETA-CRN Meeting in Lisbon 2009 [13]. Based on a
valuable paper published by Machens et al. in NEJM in
2003 [14] it is important that all European experts were
like-minded to support ATA risk classes and considered
it to be beneficial to RET mutation carriers, but the
decision about the timing of prophylactic thyroidectomy
needed to be reinforced by the Ct serum level. Irrespec-
tive of the availability of pentagastrin the Ct stimulation
test in this setting continues to play an important role
[13]. In summary, considering recently published evi-
dence [8,10] for the timing of pre-emptive thyroidect-
omy it may be concluded, that the ATA MTC
guidelines constituted a positive stimulus to publish
further evidence for Ct-guided preemptive thyroidect-
omy for RET gene mutation carriers and the conclusion
is drawn on the basis of experience expressed in Lisbon
and published later evidence that the integrated algo-
rithm based on age - calcitonin - type of RET mutation
should be considered at the decision of pre-emptive
thyroidectomy.
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